12:00 AM
Sep 10, 2015
 |  BC Innovations  |  Emerging Company Profile

Epitope as prologue

How Hummingbird develops antibodies against epitopes in natural conformation

Most antibody platforms target specific antigens, but offer little control over the exact binding location on the target or how the antibody affects activity. Hummingbird Bioscience Pte. Ltd. has developed a system for pinpointing the binding epitope and selecting antibodies that bind it in its natural configuration.

Hummingbird CEO Piers Ingram told BioCentury most companies begin with screening by peptide immunization against a target antigen to raise specific antibodies, or use phage display.

"The problem with the traditional technologies is that it is hard to control and determine how the resulting antibodies function," he said. "We know they bind the target, and we know how potently they bind, but we can't really control where they bind on that target and therefore we don't have a lot of control over the resulting therapeutic effect."

The first step of Hummingbird's two-step approach is to select the...

Read the full 702 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >